DR. A'S MONOGRAPHS

Intravenously administered high dose ascorbic acid (HDIVC) as used in cases of patients who have cancer has considerable mythology surrounding it. The purpose of this review is not to exhaustively recap the data regarding this therapy but rather to address basicissues of safety, pharmacology and outcomes of ongoing research.

Much conjecture and mythology surrounds the use of vitamin C during pregnancy. A review of clinical use and safety as well as the limited data regarding this topic leads to a different safety profile for vitamin C in pregnancy than often reported.

The pharmacologic stability of vitamins and minerals in parenteral solutions is reasonably well studied and published, but becomes a confusing data set when attempting to apply the available data to particular admixtures.

Much conjecture and mythology surrounds the use of vitamin C during pregnancy. A review of clinical use and safety as well as the limited data regarding this topic leads to a different safety profile for vitamin C in pregnancy than often reported.

Much conjecture and mythology surrounds the use of vitamin C during pregnancy. A review of clinical use and safety as well as the limited data regarding this topic leads to a different safety profile for vitamin C in pregnancy than often reported.

Oxidative versus Non-oxidative dosing of High and Low Dose Intravenous Ascorbic Acid as used by Bastyr University Clinical Research Center (BCRC) and Anderson Medical Specialty Associates (AMSA)

In an interventional study associated with BIORC and AMSA we attempted to answer the questions regarding electrolyte shifts and HDIVC administration.

The following four IV Vitamin C formulas are used for oxidative therapies.

General Treatment Protocol for the use of Intravenous Ascorbic Acid as used by Bastyr University Clinical Research Center (BCRC) and Anderson Medical Specialty Associates

HDIVC in cases of marginal GFR:

Updated Data Review and Policies for concurrent use at Anderson Medical Specialty Associates, Southwest College of Naturopathic Medicine Research Institute and Medical Center and Bastyr University Clinical Research Center

For whatever reasons this gem of an old paper is making a resurgence at many oncologists offices and being used as a justification to not start IVC, HDIVC etc.

A seeming conundrum regarding the ability of some leukemic cells (i.e. CLL) to sequester ascorbate (ASC) has led to confusion regarding the safety and utility of high dose ascorbate delivered via IV (HDIVC). This has led to some apparent confusion between this concern and the apparent positive benefits of HDIVC seen in clinical practice.

Question:

I have been told that we should wait two or more years after platinum based chemotherapy to begin any detoxification. But I have now heard conflicting information – has something changed?

Rationale and formula developed for the BIORC – AMSA Clinics during the integrative oncology study.

Glutathione
Use in cell repair and augmentation of parenteral glutathione before and after administration:
Rationale and formula developed for the BIORC – AMSA Clinics during the integrative oncology study.

As used at Anderson Medical Specialty Associates and in the Bastyr University Clinical Research Center (BCRC).